mRNA-Based Replacement Therapy

Therapeutic proteins are medicines that are genetically engineered versions of naturally occurring human proteins. Seattle Genova has been the industry leader in mRNA-based replacement therapy development for our clients.

Based on their pharmacological activity, they can be divided into five groups: 

(a) replacing a protein that is deficient or abnormal.

(b) augmenting an existing pathway.

(c) providing a novel function or activity.

(d) interfering with a molecule or organism.

(e) delivering other compounds or proteins, such as a radionuclide, cytotoxic drug, or effector proteins. 

Therapeutic proteins can also be grouped based on their molecular types that include:

antibody-based drugs

Fc fusion proteins

anticoagulants

blood factors

bone morphogenetic proteins

engineered protein scaffolds

enzymes

growth factors

hormones

interferons

interleukins

thrombolytics

They can also be classified based on their molecular mechanism of activity as:

(a) binding non-covalently to target, e.g., mAbs.

(b) affecting covalent bonds, e.g., enzymes.

(c) exerting activity without specific interactions, e.g., serum albumin. 

Modified mRNA (modRNA) is a safe, non-immunogenic, efficient, transient, local, and controlled nucleic acid delivery system that can overcome the obstacles to some traditional approaches for cardiac gene delivery. 

We have many years of experience providing advanced mRNA-based replacement therapy services to the pharmaceutical, biopharmaceutical, and biotechnology industries. At Seattle Genova, we are your true collaborative partners, helping create a scientific and operational roadmap that helps you meet your research, development, and commercial goals. We’re ready and able to help you synthesize and characterize your mRNA products in detail.

Contact Us Today

We are continuously available to discuss your needs for mRNA-based replacement therapy development and manufacturing. Our experts can help support your rapid research and development of mRNA-based replacement therapy.